Original breve
Rituximab en el tratamiento de citopenias autoinmunitarias refractarias a tratamientos convencionales
Role of rituximab in the management of refractory autoimmune cytopenia
Leído
14069
Vecesse ha leído el artículo
3473
Total PDF
10596
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 106 | 59 | 165 |
| 2025 5 | 130 | 44 | 174 |
| 2025 4 | 100 | 53 | 153 |
| 2025 3 | 85 | 35 | 120 |
| 2025 2 | 115 | 30 | 145 |
| 2025 1 | 84 | 35 | 119 |
| 2024 12 | 62 | 58 | 120 |
| 2024 11 | 81 | 74 | 155 |
| 2024 10 | 74 | 51 | 125 |
| 2024 9 | 66 | 53 | 119 |
| 2024 8 | 106 | 56 | 162 |
| 2024 7 | 116 | 42 | 158 |
| 2024 6 | 147 | 52 | 199 |
| 2024 5 | 100 | 43 | 143 |
| 2024 4 | 109 | 49 | 158 |
| 2024 3 | 107 | 34 | 141 |
| 2024 2 | 119 | 44 | 163 |
| 2024 1 | 91 | 27 | 118 |
| 2023 12 | 147 | 27 | 174 |
| 2023 11 | 120 | 60 | 180 |
| 2023 10 | 79 | 32 | 111 |
| 2023 9 | 75 | 30 | 105 |
| 2023 8 | 69 | 15 | 84 |
| 2023 7 | 93 | 37 | 130 |
| 2023 6 | 95 | 37 | 132 |
| 2023 5 | 116 | 32 | 148 |
| 2023 4 | 78 | 15 | 93 |
| 2023 3 | 96 | 23 | 119 |
| 2023 2 | 92 | 24 | 116 |
| 2022 1 | 84 | 25 | 109 |
| 2022 12 | 93 | 39 | 132 |
| 2022 11 | 131 | 59 | 190 |
| 2022 10 | 83 | 48 | 131 |
| 2022 9 | 78 | 47 | 125 |
| 2022 8 | 62 | 62 | 124 |
| 2022 7 | 43 | 51 | 94 |
| 2022 6 | 40 | 64 | 104 |
| 2022 5 | 46 | 39 | 85 |
| 2022 4 | 45 | 42 | 87 |
| 2022 3 | 80 | 74 | 154 |
| 2022 2 | 52 | 29 | 81 |
| 2021 1 | 98 | 47 | 145 |
| 2021 12 | 66 | 48 | 114 |
| 2021 11 | 76 | 52 | 128 |
| 2021 10 | 96 | 46 | 142 |
| 2021 9 | 84 | 53 | 137 |
| 2021 8 | 74 | 49 | 123 |
| 2021 7 | 67 | 45 | 112 |
| 2021 6 | 51 | 50 | 101 |
| 2021 5 | 66 | 40 | 106 |
| 2021 4 | 186 | 145 | 331 |
| 2021 3 | 141 | 58 | 199 |
| 2021 2 | 285 | 34 | 319 |
| 2020 1 | 73 | 27 | 100 |
| 2020 12 | 98 | 20 | 118 |
| 2020 11 | 62 | 28 | 90 |
| 2020 10 | 80 | 32 | 112 |
| 2020 9 | 105 | 17 | 122 |
| 2020 8 | 77 | 16 | 93 |
| 2020 7 | 66 | 16 | 82 |
| 2020 6 | 189 | 22 | 211 |
| 2020 5 | 257 | 22 | 279 |
| 2020 4 | 223 | 21 | 244 |
| 2020 3 | 127 | 21 | 148 |
| 2020 2 | 148 | 12 | 160 |
| 2020 1 | 87 | 26 | 113 |
| 2019 12 | 115 | 40 | 155 |
| 2019 11 | 75 | 18 | 93 |
| 2019 10 | 81 | 14 | 95 |
| 2019 9 | 153 | 19 | 172 |
| 2019 8 | 234 | 13 | 247 |
| 2019 7 | 176 | 33 | 209 |
| 2019 6 | 134 | 27 | 161 |
| 2019 5 | 169 | 35 | 204 |
| 2019 4 | 137 | 26 | 163 |
| 2019 3 | 80 | 23 | 103 |
| 2019 2 | 61 | 11 | 72 |
| 2019 1 | 64 | 23 | 87 |
| 2018 12 | 80 | 24 | 104 |
| 2018 11 | 114 | 24 | 138 |
| 2018 10 | 94 | 19 | 113 |
| 2018 9 | 47 | 9 | 56 |
| 2018 8 | 2 | 0 | 2 |
| 2018 7 | 6 | 0 | 6 |
| 2018 6 | 4 | 0 | 4 |
| 2018 5 | 9 | 0 | 9 |
| 2018 4 | 45 | 0 | 45 |
| 2018 3 | 30 | 0 | 30 |
| 2018 2 | 26 | 0 | 26 |
| 2018 1 | 19 | 1 | 20 |
| 2017 12 | 29 | 0 | 29 |
| 2017 11 | 29 | 0 | 29 |
| 2017 10 | 29 | 0 | 29 |
| 2017 9 | 33 | 0 | 33 |
| 2017 8 | 29 | 0 | 29 |
| 2017 7 | 37 | 0 | 37 |
| 2017 6 | 39 | 8 | 47 |
| 2017 5 | 43 | 16 | 59 |
| 2017 4 | 41 | 8 | 49 |
| 2017 3 | 38 | 34 | 72 |
| 2017 2 | 50 | 8 | 58 |
| 2016 1 | 28 | 3 | 31 |
| 2016 12 | 49 | 9 | 58 |
| 2016 11 | 92 | 8 | 100 |
| 2016 10 | 85 | 11 | 96 |
| 2016 9 | 95 | 6 | 101 |
| 2016 8 | 59 | 19 | 78 |
| 2016 7 | 43 | 11 | 54 |
| 2016 2 | 1 | 0 | 1 |
| 2015 12 | 3 | 0 | 3 |
| 2015 11 | 1 | 0 | 1 |
| 2015 10 | 0 | 19 | 19 |
| 2015 9 | 1 | 10 | 11 |
| 2015 7 | 10 | 11 | 21 |
| 2015 6 | 10 | 0 | 10 |
| 2015 5 | 2 | 0 | 2 |
| 2015 4 | 5 | 15 | 20 |
| 2015 3 | 5 | 0 | 5 |
| 2015 2 | 4 | 5 | 9 |
| 2015 1 | 6 | 1 | 7 |
| 2014 12 | 9 | 1 | 10 |
| 2014 11 | 16 | 2 | 18 |
| 2014 10 | 23 | 1 | 24 |
| 2014 9 | 16 | 1 | 17 |
| 2014 8 | 20 | 1 | 21 |
| 2014 7 | 37 | 2 | 39 |
| 2014 6 | 48 | 3 | 51 |
| 2014 5 | 50 | 6 | 56 |
| 2014 4 | 46 | 18 | 64 |
| 2014 3 | 111 | 21 | 132 |
| 2014 2 | 55 | 7 | 62 |
| 2014 1 | 70 | 15 | 85 |
| 2013 12 | 63 | 13 | 76 |
| 2013 11 | 51 | 17 | 68 |
| 2013 10 | 69 | 15 | 84 |
| 2013 9 | 64 | 26 | 90 |
| 2013 8 | 52 | 38 | 90 |
| 2013 7 | 65 | 28 | 93 |
| 2013 6 | 10 | 0 | 10 |
| 2013 5 | 293 | 0 | 293 |
Mostrar todo
